Investment bank Bryan, Garnier & Co is merging with Cartagena Capital, a technology advisory boutique headquartered in Munich, Germany. Cartagena Capital will be renamed Bryan, Garnier & Co GmbH, and the combined entity will feature one of the largest Technology, Media and Telecommunications (TMT) investment banking teams in Europe.  

IMAP Hungary-MB Partners and Concorde Corporate Finance have merged to form Concorde MB Partners, offering M&A advisory services in Hungary. The new company has several decades of transactional experience and expertise, both in the large capital markets segment and private transactions (Concorde) and the SME segment (IMAP Hungary-MB Partners).   

Cleary Gottlieb is advising pharmaceutical company Allergan on its USD160 billion merger with Pfizer which will create a new major player in the global biopharmaceuticals market.  Under the terms of the proposed transaction, the businesses of Pfizer and Allergan will be combined under Allergan plc, which will be renamed Pfizer

Aspire Ventures and Yellow Brick Capital Advisers (UK) are to merge to form Aspire Universal. Both companies share a common mission around investments in transformative companies, powered by Internet of Things (IoT) technologies, and addressing basic human needs like food & water, education, health care, shelter and finance. "Seemingly overnight,

Taylor Wessing is merging with Dutch firm Deterink. which will see the firm gain two new offices in Amsterdam and Eindhoven, covering the main financial and tech hubs of the Netherlands. Deterink is particularly known for Corporate/M&A (including Corporate Litigation), IP/IT (including Data Protection) and Employment. Its seven partners, who

Private equity firm Wellspring Capital Management has created a new flexible packaging company through the merger of portfolio companies Prolamina Corporation and newly acquired Ampac Holdings. Financial terms have not been disclosed.   The combined company, which will be headquartered in Cincinnati, Ohio, will have a strategic geographical footprint and

WuXi PharmaTech (Cayman) Inc (WuXi) has entered into a definitive Agreement and Plan of Merger  with New WuXi Life Science Limited (Parent) and WuXi Merger Limited (Merger Sub), a wholly owned subsidiary of Parent. Pursuant to the Merger Agreement, Parent will acquire the Company for cash consideration equal to USD5.75 per